Breaking News

Asymchem Passes FDA Inspection at API Mfg. Site

Reports successful FDA inspection of Tianjin 2 development and commercial manufacturing facility with no Form 483 issued

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Asymchem, a custom manufacturer of intermediates and active pharmaceutical ingredients (APIs) for the life sciences industry, announced that its Tianjin 2 site, a multi-purpose development and commercial API manufacturing facility, passed the U.S. Food and Drug Administration (USFDA) general GMP re-inspection conducted between July 23-26, 2018 with no Form 483 issued. “Our teams invest in and conduct continuous improvements to ensure the highest level of compliance and inspection readin...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters